UCB has been bringing up the rear in the IL-17 inhibitor category with bimekizumab, but now has EU approval for the drug and thinks it can mount a stiff challenge to the leaders, including Novartis' ...
Business news from the Chicago Tribune. The latest reporting on business, real estate and transportation in Chicagoland.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback